Y Intercept Hong Kong Ltd Has $7.68 Million Stake in IDEXX Laboratories, Inc. $IDXX

Y Intercept Hong Kong Ltd raised its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 149.2% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 13,665 shares of the company’s stock after purchasing an additional 8,181 shares during the period. Y Intercept Hong Kong Ltd’s holdings in IDEXX Laboratories were worth $7,678,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of IDXX. Empowered Funds LLC lifted its stake in shares of IDEXX Laboratories by 6.6% in the first quarter. Empowered Funds LLC now owns 1,538 shares of the company’s stock worth $646,000 after acquiring an additional 95 shares during the period. Sivia Capital Partners LLC bought a new position in IDEXX Laboratories during the 2nd quarter worth approximately $265,000. Jump Financial LLC lifted its position in shares of IDEXX Laboratories by 1,006.4% in the 2nd quarter. Jump Financial LLC now owns 5,532 shares of the company’s stock worth $2,967,000 after purchasing an additional 5,032 shares during the period. Cary Street Partners Financial LLC acquired a new position in shares of IDEXX Laboratories in the 2nd quarter worth approximately $164,000. Finally, Sei Investments Co. boosted its stake in shares of IDEXX Laboratories by 218.7% in the 2nd quarter. Sei Investments Co. now owns 120,587 shares of the company’s stock valued at $64,678,000 after purchasing an additional 82,755 shares during the last quarter. 87.84% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. UBS Group lowered their target price on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research note on Tuesday, April 28th. Weiss Ratings upgraded IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, June 25th. Stifel Nicolaus lowered their price objective on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research report on Tuesday, March 31st. Citigroup initiated coverage on shares of IDEXX Laboratories in a research note on Wednesday, April 15th. They set a “neutral” rating and a $650.00 target price on the stock. Finally, Wall Street Zen raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Saturday, June 13th. Seven equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and a consensus target price of $751.00.

IDEXX Laboratories Stock Performance

NASDAQ IDXX opened at $557.80 on Friday. The company has a fifty day simple moving average of $555.31 and a 200 day simple moving average of $609.16. IDEXX Laboratories, Inc. has a 12-month low of $506.91 and a 12-month high of $769.98. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19. The company has a market cap of $44.00 billion, a P/E ratio of 41.08, a PEG ratio of 3.05 and a beta of 1.55.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, topping the consensus estimate of $3.41 by $0.06. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The firm had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.12 billion. During the same quarter in the prior year, the company posted $2.91 earnings per share. The business’s revenue was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Sell-side analysts predict that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.